New hope for ITP patients: experimental drug aims to boost platelets
NCT ID NCT05885555
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants have already tried steroids and another standard treatment. The study measures whether ianalumab can safely raise platelet counts to a safe level.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ianalumab (a biologic drug given by IV infusion)
What this could lead to
If successful, this could offer a new treatment option for people with ITP whose disease hasn't responded well to standard therapies.
What could go wrong
This is a small, early-phase trial with only 41 participants, so results may not apply to everyone. The drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Med Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
CABA, C1181ACH, Argentina
-
Novartis Investigative Site
Garran, Australian Capital Territory, 2605, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Jinan, 250012, China
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Giessen, 35392, Germany
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Johor Bahru, 80100, Malaysia
-
Novartis Investigative Site
Katowice, 40-519, Poland
-
Novartis Investigative Site
Seoul, 06591, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08003, Spain
-
Novartis Investigative Site
Aydin, Efeler, 09100, Turkey (Türkiye)
-
Novartis Investigative Site
Istanbul, Fatih, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
Edirne, Merkez, 22030, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Kocaeli, 41380, Turkey (Türkiye)
-
Novartis Investigative Site
Glasgow, G31 2ER, United Kingdom
-
Novartis Investigative Site
London, W12 0HS, United Kingdom